Cancer Related Mutations in NRF2 Impair Its Recognition by Keap1-Cul3 E3 Ligase and Promote Malignancy

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2008 Sep 2

PMID 18757741

Citations 368

Authors

Tatsuhiro Shibata

Tsutomu Ohta

Kit I Tong

Akiko Kokubu

Reiko Odogawa

Koji Tsuta

Hisao Asamura

Masayuki Yamamoto

Setsuo Hirohashi

Affiliations

Soon will be listed here.

Abstract

The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents. Under normal, nonstressed circumstances, low cellular concentrations of Nrf2 are maintained by proteasomal degradation through a Keap1-Cul3-Roc1-dependent mechanism. A model for Nrf2 activation has been proposed in which two amino-terminal motifs, DLG and ETGE, promote efficient ubiquitination and rapid turnover; known as the two-site substrate recognition/hinge and latch model. Here, we show that in human cancer, somatic mutations occur in the coding region of NRF2, especially among patients with a history of smoking or suffering from squamous cell carcinoma; in the latter case, this leads to poor prognosis. These mutations specifically alter amino acids in the DLG or ETGE motifs, resulting in aberrant cellular accumulation of Nrf2. Mutant Nrf2 cells display constitutive induction of cytoprotective enzymes and drug efflux pumps, which are insensitive to Keap1-mediated regulation. Suppression of Nrf2 protein levels by siRNA knockdown sensitized cancer cells to oxidative stress and chemotherapeutic reagents. Our results strongly support the contention that constitutive Nrf2 activation affords cancer cells with undue protection from their inherently stressed microenvironment and anti-cancer treatments. Hence, inactivation of the Nrf2 pathway may represent a therapeutic strategy to reinforce current treatments for malignancy. Congruously, the present study also provides in vivo validation of the two-site substrate recognition model for Nrf2 activation by the Keap1-Cul3-based E3 ligase.

Citing Articles

Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.

Data-Driven Molecular Typing: A New Frontier in Esophageal Cancer Management.

Du Y, Gu B, Shi L, She Y, Zhao Q, Gao S Cancer Med. 2025; 14(5):e70730.

PMID: 40018789 PMC: 11868787. DOI: 10.1002/cam4.70730.

KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.

Oskomic M, Tomic A, Barbaric L, Matic A, Kindl D, Matovina M Cancers (Basel). 2025; 17(3).

PMID: 39941813 PMC: 11816071. DOI: 10.3390/cancers17030447.

A histochemical approach to activity-based copper sensing reveals cuproplasia-dependent vulnerabilities in cancer.

Messina M, Torrente L, Pezacki A, Humpel H, Li E, Miller S Proc Natl Acad Sci U S A. 2025; 122(3):e2412816122.

PMID: 39813247 PMC: 11761388. DOI: 10.1073/pnas.2412816122.

Splicing junction-based classifier for the detection of abnormal constitutive activation of the KEAP1-NRF2 system.

Mateos R, Winardi W, Chiba K, Okada A, Suzuki A, Mitsuishi Y NPJ Syst Biol Appl. 2024; 10(1):147.

PMID: 39643653 PMC: 11624210. DOI: 10.1038/s41540-024-00475-w.

References

Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M . Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008; 68(5):1303-9. DOI: 10.1158/0008-5472.CAN-07-5003. View

Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K . Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004; 64(18):6424-31. DOI: 10.1158/0008-5472.CAN-04-1906. View

Tong K, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M . Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006; 26(8):2887-900. PMC: 1446969. DOI: 10.1128/MCB.26.8.2887-2900.2006. View

Wu L, Wang Z, Tsan J, Spillman M, Phung A, Xu X . Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet. 1996; 14(4):430-40. DOI: 10.1038/ng1296-430. View

Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel J . Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13(1):76-86. PMC: 316370. DOI: 10.1101/gad.13.1.76. View

Motohashi H, Yamamoto M . Carcinogenesis and transcriptional regulation through Maf recognition elements. Cancer Sci. 2006; 98(2):135-9. PMC: 11159501. DOI: 10.1111/j.1349-7006.2006.00358.x. View

Petroski M, Deshaies R . Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005; 6(1):9-20. DOI: 10.1038/nrm1547. View

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

10.

Kasai H, Kawai K . Oxidative DNA damage: mechanisms and significance in health and disease. Antioxid Redox Signal. 2006; 8(5-6):981-3. DOI: 10.1089/ars.2006.8.981. View

11.

Kensler T, Wakabayashi N, Biswal S . Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2006; 47:89-116. DOI: 10.1146/annurev.pharmtox.46.120604.141046. View

12.

Ramos-Gomez M, Kwak M, Dolan P, Itoh K, Yamamoto M, Talalay P . Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(6):3410-5. PMC: 30667. DOI: 10.1073/pnas.051618798. View

13.

Kobayashi A, Kang M, Okawa H, Ohtsuji M, Zenke Y, Chiba T . Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24(16):7130-9. PMC: 479737. DOI: 10.1128/MCB.24.16.7130-7139.2004. View

14.

Stuart A, Fiser A, Sanchez R, Melo F, Sali A . Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000; 29:291-325. DOI: 10.1146/annurev.biophys.29.1.291. View

15.

Zhang D, Lo S, Cross J, Templeton D, Hannink M . Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004; 24(24):10941-53. PMC: 533977. DOI: 10.1128/MCB.24.24.10941-10953.2004. View

16.

Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S . Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003; 35(3):238-45. DOI: 10.1038/ng1248. View

17.

Marzec J, Christie J, Reddy S, Jedlicka A, Vuong H, Lanken P . Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 2007; 21(9):2237-46. DOI: 10.1096/fj.06-7759com. View

18.

Kim W, Kaelin W . Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22(24):4991-5004. DOI: 10.1200/JCO.2004.05.061. View

19.

Singh A, Misra V, Thimmulappa R, Lee H, Ames S, Hoque M . Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3(10):e420. PMC: 1584412. DOI: 10.1371/journal.pmed.0030420. View

20.

Lo S, Li X, Henzl M, Beamer L, Hannink M . Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006; 25(15):3605-17. PMC: 1538563. DOI: 10.1038/sj.emboj.7601243. View